NCT02629991View on ClinicalTrials.gov

Oxytocin vs. Placebo for the Treatment Hyperphagia in Children and Adolescents With Prader-Willi Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

December 31, 2016

Study Completion Date

May 31, 2018

Conditions
Prader-Willi SyndromeHyperphagia
Interventions
DRUG

Intranasal Oxytocin (IN-OXT)

Participants were instructed to take 16 IU/per day everyday (2 puffs per nostril, 4 IU each puff).

OTHER

Matched Placebo

Participants were instructed to take 16 IU/per day everyday (2 puffs per nostril, 4 IU each puff).

Trial Locations (1)

10467

Montefiore Medical Center, Albert Einstein College of Medicine, The Bronx

All Listed Sponsors
collaborator

Foundation for Prader-Willi Research

OTHER

lead

Montefiore Medical Center

OTHER

NCT02629991 - Oxytocin vs. Placebo for the Treatment Hyperphagia in Children and Adolescents With Prader-Willi Syndrome | Biotech Hunter | Biotech Hunter